Form 4: Kiniksa Pharmaceuticals Executive Eben Tessari Executes Stock Transactions Under 10b5-1 Plan
SEC Form 4 Filing
Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, executed multiple transactions involving Class A Ordinary Shares and share options, including both acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.
Summary
- Eben Tessari, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, engaged in transactions involving the company's Class A Ordinary Shares on November 18, 2024.
- These transactions included the acquisition of 10,000 Class A Ordinary Shares at a price of $1.59 per share and the disposal of 17,000 Class A Ordinary Shares at a weighted average price of $21.04 per share.
- The transactions were executed under a pre-arranged 10b5-1 trading plan established on April 29, 2024.
- Additionally, Tessari exercised a share option for 10,000 shares at a price of $1.59 per share.
- Following these transactions, Tessari directly owns 102,975 Class A Ordinary Shares and 16,017 share options.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing insider transactions, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests the transactions were pre-planned and not based on any new information.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any material non-public information.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
- The reported transactions are typical for executives who hold stock options and shares in their company.
- Similar filings are regularly made by executives at comparable pharmaceutical companies such as Regeneron, Vertex, and BioMarin.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but are unlikely to significantly affect the company's overall performance or stakeholder value.
Key Dates
| Date | Description |
|---|---|
| 04/29/2024 | Date the 10b5-1 trading plan was executed by the reporting person. |
| 11/18/2024 | Date of the reported transactions, including the acquisition and disposal of shares and the exercise of share options. |
| 11/20/2024 | Date the SEC Form 4 was signed. |
| 12/15/2025 | Expiration date of the share option. |
Keywords
Kiniksa Pharmaceuticals, Eben Tessari, Class A Ordinary Shares, Share Option, 10b5-1 Plan, SEC Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.